Retracted and republished from: "The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs".

Influenza viruses (IVs) threaten global human health due to the high morbidity, infection, and mortality rates. Currently, the influenza drugs recommended by the Food and Drug Administration are oseltamivir, zanamivir, peramivir, and baloxavir marboxil. These recommended antivirals are currently effective for major subtypes of IVs as the compounds target conserved domains in neuraminidase or polymerase acidic (PA) protein. However, this trend may gradually change due to the selection of antiviral drugs and the natural evolution of IVs. Therefore, there is an urgent need to develop drugs related to the treatment of influenza to deal with the next pandemic. Here, we summarized the cutting-edge research in mechanism of action, inhibitory activity, and clinical efficacy of drugs that have been approved and drugs that are still in clinical trials for influenza treatment. We hope this review will provide up-to-date and comprehensive information on influenza antivirals and generate hypotheses for screens and development of new broad-spectrum influenza drugs in the near future.

Bioavailability-based risk assessment of various heavy metals via multi-exposure routes for children and teenagers in Beijing, China.

Assessing the health risks of sensitive population, such as children and teenagers, through multiple exposure routes (MERs) such as ingestion, inhalation, and dermal contact is critical for policy creation that protects or reduces exposure to pollutants for all populations. Heavy metal (HM) contents in food and environmental media in Beijing, capital of China, were collected. Furthermore, on the basis of considering the bioavailability of HMs, we evaluated the multiple environmental routes and health risks to HMs in children and teenagers of eight age groups (2-<3, 3-<4, 4-<5, 5-<6, 6-<9, 9-<12, 12-<15, and 15-<18) in Beijing, China by Monte Carlo simulation approach. The main findings are as follows: lead exposure in children aged 2-<3 years exceeds the exposure dose (0.3 µg·kg-1·d-1) of 0.5 point reduction in intelligence quotient. Moreover, children aged 2-<3 and 6-<9 years have relatively high non-carcinogenic risk (NCR) of 1.32 and 1.30, respectively. The carcinogenic risk (CR) for children aged 6-<9 and 9-<12 years is 2.73×10-6 and 2.39×10-6, respectively. Specifically, the contributions of oral ingestion, dermal contact, and inhalation to the NCR were 69.5%, 18.9%, and 11.6%, respectively. Moreover, the combined NCR contributions of copper, cadmium, mercury, and arsenic (As) were about 69.4%. The contributions of the above three routes to the CR were 93.4%, 4.1%, and 2.5%, in that order, with the largest CR contribution of As being about 92.0%. This study can provide new ideas for accurately assessing the exposure and health risks of HMs in the population, and we believe that it is necessary to update the national standards for food and soil based on the bioavailability of HMs.

The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs.

Influenza viruses (IVs) threaten global human health due to the high morbidity, infection, and mortality rates. Currently, the influenza drugs recommended by the FDA are oseltamivir, zanamivir, peramivir, and baloxavir marboxil. Notably, owing to the high variability of IVs, no drug exists that can effectively treat all types and subtypes of IVs. Moreover, the current trend of drug resistance is likely to continue as the viral genome is constantly mutating. Therefore, there is an urgent need to develop drugs related to the treatment of influenza to deal with the next pandemic. Here, we summarized the cutting-edge research in mechanism of action, inhibitory activity, and clinical efficacy of drugs that have been approved and drugs that are still in clinical trials for influenza treatment. We hope this review will provide up-to-date and comprehensive information on influenza antivirals and generate hypotheses for screens and development of new broad-spectrum influenza drugs in the near future.